These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 10199464)
1. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Patt YZ; Hoque A; Roh M; Ellis L; Lozano R; Carrasco CH; Charnsangavej C; Cleary K Am J Clin Oncol; 1999 Apr; 22(2):209-13. PubMed ID: 10199464 [TBL] [Abstract][Full Text] [Related]
2. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567 [TBL] [Abstract][Full Text] [Related]
3. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Kaseb AO; Shindoh J; Patt YZ; Roses RE; Zimmitti G; Lozano RD; Hassan MM; Hassabo HM; Curley SA; Aloia TA; Abbruzzese JL; Vauthey JN Cancer; 2013 Sep; 119(18):3334-42. PubMed ID: 23821538 [TBL] [Abstract][Full Text] [Related]
4. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Akçali Z; Akin E; Ozyilkan O Cancer; 2002 Nov; 95(9):2038-9; author reply 2039. PubMed ID: 12404300 [No Abstract] [Full Text] [Related]
5. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K Int J Clin Oncol; 2011 Jun; 16(3):221-9. PubMed ID: 21132451 [TBL] [Abstract][Full Text] [Related]
6. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b. Mawatari H; Kirikoshi H; Yoneda M; Higurashi T; Fujita K; Saito S; Inamori M; Takahashi H; Abe Y; Kubota K; Nakajima A Hepatogastroenterology; 2008; 55(86-87):1776-7. PubMed ID: 19102391 [TBL] [Abstract][Full Text] [Related]
7. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study. Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574 [TBL] [Abstract][Full Text] [Related]
8. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Urabe T; Kaneko S; Matsushita E; Unoura M; Kobayashi K Oncology; 1998; 55(1):39-47. PubMed ID: 9428374 [TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061 [TBL] [Abstract][Full Text] [Related]